ArticleFrontiers in pharmacology2026

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance.

Mengqing Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.